Key Takeaways Karyopharm Therapeutics stock fell 18% after mixed phase III SENTRY results in myelofibrosis.KPTI combo met the SVR35 endpoint with 50% response but missed the symptom score improvement goal.Karyopharm Therapeutics saw similar symptom scores vs Jakafi, while the survival trend needs longer follow-up.Shares of Karyopharm Therapeutics (KPTI) plunged 18.3% on Tuesday after the company reported mixed top-line results from a late-stage study evaluating a 60 mg dose of selinexor in combination with ...